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Abstract
Background: Most sporadic colorectal cancer (sCRC) deaths are caused by metastatic dissemination of the primary tumor.
New advances in genetic profiling of sCRC suggest that the primary tumor may contain a cell population with metastatic
potential. Here we compare the cytogenetic profile of primary tumors from liver metastatic versus non-metastatic sCRC.
Methodology/Principal Findings: We prospectively analyzed the frequency of numerical/structural abnormalities of
chromosomes 1, 7, 8, 13, 14, 17, 18, 20, and 22 by iFISH in 58 sCRC patients: thirty-one non-metastatic (54%) vs. 27
metastatic (46%) disease. From a total of 18 probes, significant differences emerged only for the 17p11.2 and 22q11.2
chromosomal regions. Patients with liver metastatic sCRC showed an increased frequency of del(17p11.2) (10% vs.
67%;p,.001) and del(22q11.2) (0% vs. 22%;p = .02) versusnon-metastatic cases. Multivariate analysis of prognostic factors
for overall survival (OS) showed that the only clinical and cytogenetic parameters that had an independent adverse impact
on patient outcome were the presence of del(17p) with a 17p11.2 breakpoint and del(22q11.2). Based on these two
cytogenetic variables, patients were classified into three groups: low- (no adverse features), intermediate- (one adverse
feature) and high-risk (two adverse features)- with significantly different OS rates at 5-years (p,.001): 92%, 53% and 0%,
respectively.
Conclusions/Significance: Our results unravel the potential implication of del(17p11.2) in sCRC patients with liver
metastasis as this cytogenetic alteration appears to be intrinsically related to an increased metastatic potential and a poor
outcome, providing additional prognostic information to that associated with other cytogenetic alterations such as
del(22q11.2). Additional prospective studies in larger series of patients would be required to confirm the clinical utility of the
new prognostic markers identified.
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Introduction
Metastatic dissemination of the primary tumor is the major
cause of death of sporadic colorectal cancer (sCRC) patients [1].
Metastasis is a complex multi-step process which is driven by
sequential accumulation of multiple genetic and molecular
alterations and/or epigenetic changes involving one or multiple
tumor cell clones. In recent years, data accumulated about the
intratumoral pathways of clonal evolution of sCRC associated with
chromosomal alterations/instability, indicates that liver metastatic
lesions may derive from descendants of a tumor cell clone which is
already present in the primary tumor [2]. Advances in genetic
profiling of cancer also suggest that the metastatic potential of
human tumors is encoded in the bulk of a primary tumor, as
metastatic tumors systematically contain those genetic abnormal-
ities observed in the primary tumor sample from the same subject.
However, the precise molecular changes associated with the
development of sCRC with liver metastasis still remain to be
identified [2]. Multiple recurrent chromosomal abnormalities that
are found in primary tumours have been associated with
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metastatic CRC, including gains of chromosomes 8q, 13q and 20q
and losses of the 1p, 8p, 17p, 18q and 22q chromosomal regions
[3–5].
In a recent study, we described a detailed map of the genetic
abnormalities of primary tumors from sCRC patients with liver
metastasis by high-resolution SNP arrays. In this study, we
reported the existence of a highly prevalent breakpoint region in
the great majority of primary sCRC patients who had synchronous
liver metastasis. Such breakpoint region is located in the
centromeric region of chromosome 17p, between the genome
coordinates 20,156,497 bp and 22,975,771 bp [6]. This break-
point region has been previously associated with i) a homogeneous
genetic profile consisting of a higher frequency of abnormalities of
chromosomes 1p, 7, 8, 13q, 17p, 18q, 20q and 22q and ii) an
adverse clinical outcome [7]. However, delineation of the minimal
common breakpoint region at chromosome 17p11.2 and its
potential prognostic value in sCRC tumors, remain to be fully
defined.
In the present study we investigated the prognostic value of
structural/numerical abnormalities of the most frequently altered
chromosomes in liver metastatic colorectal carcinomas from 58
sCRC patients (27 liver metastatic vs. 31 non-metastatic tumors)
with a long median follow-up, as detected by interphase
fluorescence in situ hybridization (iFISH). Overall, our results
show that the occurrence of del(17p) involving the 17p11.2
breakpoint region is an independent prognostic factor for overall
survival, as confirmed in a larger series of 119 patients from the
GEO public database. However, we have demonstrated that the
combined assessment of del(22q11) and del(17p11.2) increased the
predictive value for a liver metastatic tumor.
Materials and Methods
Patients and samples
In the present study, we prospectively analyzed surgical
specimens from 58 patients diagnosed with a sCRC between
1999 and 2010 (38 males and 20 females; median age of 69 years,
ranging from 38 to 83 years) after informed consent was given by
each subject. All patients underwent surgical resection of primary
tumor tissues at the Department of Surgery of the University
Hospital of Salamanca (Salamanca, Spain) and they were
diagnosed and classified according to the WHO criteria [8] prior
to any treatment was given. Fourteen primary tumors were
localized in the rectum and the other 44 were localized either in
the right (caecum, ascending or trasverse) or the left (descending
and sigmoid) colon, with an overall mean size of 5.362 cm.
According to tumor grade, 39 cases were classified as well-
differentiated tumors, 15 as moderately- and four as poorly-
differentiated carcinomas. In all cases, histopathological grade was
confirmed in a second independent evaluation by an experienced
pathologist. Median follow-up at the moment of closing this study
was of 96 months (range: 12–124 months). The study was
approved by the local ethics committee of the University Hospital
of Salamanca (Salamanca, Spain) and informed consent was given
by each individual, prior to entering the study.
From the 58 cases analyzed, 27 (47%) tumors had liver
metastases (group 1; median follow-up of 37 months; pT3–4 pN1–
2 M1) identified either at time of colorectal surgery (n = 16) or
during the first year after initial diagnosis (n = 11); they all
underwent complete surgical resection of both their primary and
metastatic CRC. The other 31 (53%) patients corresponded to
non-metastatic sCRC selected on the basis of a long follow-up in
the absence of liver metastasis (median follow-up of 99 months;
pT2–4 pN0 M0) to ensure their non-metastatic nature (group 2).
After histopathological diagnosis was established, part of the
primary tumor was used to prepare single-cell suspensions. Once
prepared, single cell suspensions were resuspended in methanol/
acetic (3/1; vol/vol) and stored at 220uC for further iFISH
analyses, as described elsewhere [2]. The remaining tissue was
either fixed in formalin and embedded in paraffin, or frozen in
liquid nitrogen and stored at room temperature (RT) and at
280uC, respectively. Each individual tissue sample was also
evaluated after haematoxylin-eosin staining, to confirm the
presence of tumor cells and to evaluate their quantity.
Interphase fluorescence in situ hybridization (iFISH)
studies
Mixed single-cell suspensions from different samples obtained
from each tumor were used for iFISH studies, after fixation in 3/1
methanol/acetic (vol/vol). A set of 18 different probes (Vysis Inc,
Downers Grove, IL) specific for those chromosomes and
chromosomal regions most frequently gained/amplified and
deleted colorectal carcinomas with liver metastases [6], were
systematically used in double and triple staining with the Spectrum
Orange (SO), Spectrum Green (SG) and Spectrum Aqua (SA)
fluorochromes: for chromosome 1, the LSI p58 (1p36) (SO)/
TelVysion 1p (SG)/LSI 1q25 (SA) Multi-color probe was
employed; for chromosome 7, the LSI D7S486 (7q31) (SO)/
CEP 7 (SG) Dual Color probe was used; for chromosome 8, the
LSI LPL (8p22) (SO)/CEP 8 (SA)/MYC (8q24) (SG) Multi-color
probe was employed; for chromosome 13, the LSI RB1 13q14
(SO)/LSI 13q34 LAMP1 (SG) was used; for chromosome 14, the
LSI IGH (14q32.33) Dual Color, Break Apart probe was selected;
for chromosome 17, the LSI TP53 (17p13) (SO)/CEP 17 (SA)
probe combination was employed; for chromosome 18, the LSI
BCL2 (18q21) (SO)/CEP 18 (SA) probe combination was used; for
chromosome 20, the LSI ZNF217 (20q13.2) (SO)/CEP 20 (SG)
probes were employed, and; for chromosome 22, the LSI BCR
(22q11.2) probe was used. We have previously found in primary
tumors [6] and their paired liver metastases [9] a high prevalence
of gains of chromosomes 7, 8q, 11q, 13q, 20q and X together with
losses of the 1p, 8p, 17p and 18q chromosomal regions; in this
series of cases, the breakpoints found at the centromeric region of
chromosome 17p were variable and were mapped between the
genomic coordinates 20,156,497 bp and 22,975,771 bp by SNP’s
arrays. Herein, we investigated the presence of breakpoints at
chromosome 17p11.2 using iFISH probes specifically designed
and manufactured for this purpose (Kreatech Diagnostics,
Amsterdam, The Netherlands), as schematically described in
Figure 1.
The specific methods and procedures used for the iFISH studies
have been previously described in detail [2] and for the
investigation of the relationships existing between those genes
coded at the 17p11.2, 17p13.1 and 22q11.2 chromosomal regions
and other genes, the Ingenuity Pathway Analysis software
(Ingenuit SystemH,www.ingenuity.com) was used.
External validation of the prognostic impact of del(17p)
and del(22q)
External validation of the prognostic impact of del(17p) and
del(22q) was performed in a previously reported group of sCRC
patients from which aCGH files (MHP Human 1 Mb) and clinical
data were publicly available at the GEO database (accession
number GSE12520; genomic markers that predict survivorship in
colorectal cancer) [10]. From all cases available in the dataset, we
selected those studied with the MHP Human 1 Mb CGH array
platform for a total of 109 cases: 81 sCRC from Edinburgh
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(Scotland, UK) and 38 from Hong Kong. Gpr files were pre-
processed and normalized as described elsewhere [11]. Patients
included in this external validation group were classified according
to the Duke’s staging system as follows: stage A, 7.5% (n= 8), B,
44.9% (n= 48), C, 39.2% (n= 42) and stage D (metastatic), 8.5%
(n= 9). Median of follow up of these patients was 67 months, with
a median overall survival of 28.7months (range: 0.3–147.2
months).
Statistical methods
For all continuous variables, mean values and their standard
deviation (SD) and range were calculated using the SPSS software
package (SPSS 15.0 Inc, Chicago, IL USA); for dichotomic
variables, frequencies were reported. In order to evaluate the
statistical significance of differences observed between groups, the
Student’s T and the Mann-Whitney U tests were used for
continuous variables, depending on whether they displayed or not
a normal distribution, respectively. For qualitative variables, the
X2 test was applied (cross-tab; SPSS). Overall survival (OS) curves
were plotted according to the method of Kaplan and Meier, and
the log-rank test (one-sided) was used to establish the statistical
significance of the differences observed between survival curves
(survival; SPSS). Multivariate analysis of prognostic factors for OS
was performed using the Cox stepwise regression (forward
selection) model (regression, SPSS). For multivariate analysis only
those variables showing a significant association with OS in the
univariate analysis were included. Statistical significance was
considered to be present once P values (or, where appropriate,
Pearson-corrected P values) were ,.05.
Results
Clinical and biological characteristics of liver metastatic
versus non-metastatic sporadic colorectal carcinoma
(sCRC)
Overall, sCRC cases with liver metastases showed a higher
frequency of lymph node metastases (p#.001) and abnormally
increased CEA serum levels (p#.001) than non-metastatic patients
(Table 1). From the prognostic point of view, sCRC with liver
metastases also showed a higher frequency of deaths in association
Figure 1. Schematic representation of the chromosome 17p11.2 dual color Break Apart probe combination designed and used for
iFISH analysis of this chromosomal region in sCRC. Panel A describes the probe design for which three different clones (A, B and C) directly-
labelled with PlatinumBright495 (green signal) and that hybridize to the telomeric part of the 20,156,497 bp region were combined with another
three clones (clones D, E and F) directly labelled with PlatinumBright550 and that correspond to sequences harboured centromerically to
20,156,497 bp (red signal), and were produced. The 17p11.2 Break Apart DNA Probe finally consisted of a dual-color assay to detect breakpoints at
17p11.2 using the combination of these 6 fluorescently labelled clones. A positive breakpoint at chromosome 17p11.2 was defined when one or two
red/green or yellow fusion signals split into two separate red and green signals. Only red and green signals which were more than one signal
diameter apart from each other were counted as reflecting a chromosome break, since based on the probe design a gap of 380 KB exists between
the two sets of probes corresponding to the green and the red signals, respectively; two fusion signals identify the two normal chromosomes 17 as
illustrated for the lower nuclei shown in panel B. Loss of a green signal in the presence of a single red signal and a fusion signal was interpreted as
associated with del(17p) with a 17p11.2 breakpoint (e.g; three upper nuclei in panel B).
doi:10.1371/journal.pone.0042683.g001
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with a significantly shortened patient overall survival (median of 25
months vs. not reached, respectively; p#.001). By contrast, no
significant differences were found between liver metastatic vs. non-
metastatic CRC cases, regarding patient age, gender, tumor
localization, histological grade and size, and alkaline phosphatase
serum levels (Table 1).
Chromosomal alterations in metastatic vs non-metastatic
sCRC
For most chromosomes analysed, sCRC with liver metastases
showed similar cytogenetic profiles to those of non-metastatic
tumors; this included similar (p..05) frequencies of del(1p) (48%
vs. 42%), polysomy of chromosome 7 (59% vs. 45%), del(8p)
associated to gains of 8q (44% vs. 26%), polysomy of chromosome
13 (74% vs. 58%), del(18q) (52% vs. 32%) and gain of chromosome
20q (63% vs. 39%) (Table 2). The only statistically significant
differences found between liver metastatic and non-metastatic
sCRC were those involving chromosomes 17p (p,.001) and 22q
(p = .02): all cases showing del(22q) corresponded to liver
metastatic tumors (0% vs. 22%); del(17p13) was found in 74% of
liver metastatic vs. 19% of non-metastatic cases; del(17p13) with a
breakpoint at 17p11.2 was almost exclusively detected among
sCRC with liver metastases (67% vs. 10%, p,.001) (Table 2), and;
all except one case with del(22q) (n = 5) also demonstrated
del(17p11.2) while16 cases which had del(17p11.2) did not carry
del(22q). The remaining 36 tumors carried none of the two
chromosomal alterations. Interestingly, whenever these two
chromosomal alterations were detected, either individually or in
combination, they were present in all tumor cells, suggesting they
had been acquired in the ancestral tumor cell clone.
Overall, a total of 36 genes are coded at the 17p11.2, 17p13.1
and 22q11.2 chromosomal regions (Table 3); 11 out of these 36
genes (31%) have been found to be involved in cancer. The
network of functional interactions among these genes and other
related downstream genes implicated in cancer is depicted in
Figure 2. As shown in it, such cancer-associated genes deleted in
sCRC cases with del(17p11.2) and del(22q11.2) directly related to
several well-established biomarkers of sCRC such as the EGFR,
BCL2, BAX and TP53 genes [12–15].
Impact of chromosomal alterations and other disease
features of liver metastatic vs. non-metastatic sCRC on
patient overall survival
Regarding prognosis, the presence of both del(17p13) (p = .04) -
including del(17p11.2) (p,.001)- and del(22q11) (p,.001) were
associated with a significantly inferior outcome. Other disease
features that showed an adverse impact on patient OS were:
increased (.7.5 ng/ml) CEA serum levels (p,.001), male gender
(p = .04), lymph node involvement (p,.001) and, metastatic liver
disease (p,.001) (Figure 3).
Multivariate analysis of the prognostic factors for OS showed
that the most informative combination of independent variables to
predict an adverse outcome was the presence of del(17p11.2)
(p = .04) and del(22q11.2) (p = .002). Based on these two cytoge-
Table 1. Clinical and biological characteristics of liver metastatic (n = 27) versus non-metastatic (n = 31) sporadic colorectal
carcinoma (sCRC) patients.
Liver metastatic sCRC (n=27)
Non-metastatic sCRC
(n =31) p-value Total cases (n=58)
Age (years)* 73 (48–80) 72 (38–83) NS 72 (38–83)
Gender
F 11 (41%) 9 (29%) NS 20 (34%)
M 16 (59%) 22 (71%) 38 (66%)
Tumor Localization
Rectum 5 (19%) 11 (36%) 16 (28%)
Left colon 13 (48%) 15 (48%) NS 28 (52%)
Right colon 9 (33%) 5 (16%) 14 (20%)
Histological grade
Well-differentiated 16 (59%) 23 (74%) 39 (67%)
Moderate-differentiated 8 (30%) 7 (22%) NS 15 (26%)
Poorly-differentiated 3 (11%) 1(4%) 4 (7%)
Histopathology
pN0 7 (26%) 31 (100%) 38 (66%)
pN1 12 (44%) 0 (0%) p#0.001 12(21%)
pN2 8 (30%) 0 (0%) 8 (13%)
Tumor Size (cm)# 5 (2.5–9) 5 (2.5–14) NS 5 (2.5–14)
Serum ALP (mg/dl) 94 (1–330) 108 (55–495) NS 101 (1–495)
Serum CEA (ng/ml) 45.4 (0.8–4598) 3.2 (0.6–84) p#0.001 7.2 (0.6–4598)
Deaths 20 (74%) 3 (10%) p#0.001 23 (40%)
Median OS (months)* 25 Not Reached p#0.001 Not Reached
*Results expressed as median (range) or
#as number of cases (percentage); NS: statistically not significant (p..05); F: female; M: male; ALP: alkaline phosphatase; CEA: Carcinoembryonic antigen; OS: overall
survival.
doi:10.1371/journal.pone.0042683.t001
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netic variables, a scoring system was built to stratify patients into a
low- (no adverse features: score 0; n = 24), intermediate- (one
adverse feature: score 1; n= 28) and high-risk (two adverse
features: score 2; n= 5) groups with significantly different (p,.001)
OS rates at 5-years: 92%, 53% and 0%, respectively (Figure 3).
Validation of the clinical impact of del(17p11.2) and
del(22q) in an independent series of patients
In order to confirm the prognostic impact of the two
chromosomal abnormalities described above, we investigated their
prognostic impact in an independent series of colorectal cancer
patients from the public GEO database (n = 119). Noteworthy,
also in this new series, patients whose tumors harboured
pericentromeric breakpoints at 17p in the 17p11.2 chromosomal
Table 2. Chromosomal alterations of primary tumors from liver metastatic (n = 27) versus non-metastatic sCRC patients (n = 31).
Liver metastatic tumors
(n=27) Non-metastatic tumors (n =31)p-value Total cases (n=58)
Chromosome 1
Normal 7 (26%) 14 (45%) 21 (36%)
del(1p) 13 (48%) 13 (42%) NS 26 (45%)
Polysomy 7 (26%) 4 (13%) 11 (19%)
Chromosome 7
Normal 5 (19%) 14 (45%) 19 (33%)
del(7q) 5 (19%) 1 (3%) NS 6 (10%)
q+ 1 (3%) 2 (7%) 3 (5%)
Polysomy 16 (59%) 14 (45%) 30 (52%)
Chromosome 8
Normal 3 (11%) 7 (23%) 10 (17%)
del(8p) 5 (19%) 4 (13%) 9 (15%)
q+ 2 (7%) 3 (9%) NS 5 (9%)
Del(8p)/8q+ 12 (44%) 8 (26%) 20 (35%)
Polysomy 5 (19%) 9 (29%) 14 (24%)
Chromosome 13
Normal 7 (26%) 13 (42%) NS 20 (35%)
Polysomy 20 (74%) 18 (58%) 38 (65%)
Chromosome 14
Normal 15 (55%) 19 (61%) 34(59%)
del(14q) 4 (15%) 1 (3%) NS 5 (9%)
Polysomy 8 (30%) 11 (36%) 19 (32%)
Chromosome 17
Normal 5 (19%) 20 (65%) 25 (43%)
del(17p) 20 (70%) 6 (19%) p,.001 26 (45%)
Polysomy 2 (7%) 5 (16%) 7 (12%)
Del(17p11.2) 18 (67%) 3 (10%) p,.001 21 (36%)
Chromosmose 18
Normal 13 (48%) 17 (55%) 30 (52%)
del(18q) 14 (52%) 10 (32%) NS 29 (50%)
Polysomy 0 (0%) 4 (13%) 4 (7%)
Chromosome 20
Normal 5 (19%) 12 (39%) 17 (27%)
20q+ 17 (63%) 12 (39%) NS 29 (50%)
Polysomy 5 (19%) 7 (22%) 12 (21%)
Chromosome 22
Normal 15 (56%) 23 (74%) 38 (66%)
del(22q) 6 (22%) 0 (0%) p= .02 6 (10%)
Polysomy 6 (22%) 8 (26%) 14 (24%)
Results expressed as number of cases and percentage of cases between brackets; NS: statistically not significant (p..05).
doi:10.1371/journal.pone.0042683.t002
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region (from 15 to 25 megabases from p-ter) were found to have an
inferior clinical outcome than those harbouring del(17p13) alone
(p = .02 and p= .04, respectively). The prognostic impact of
del(17p11.2) was even stronger (p = .01) when all other tumors
which showed pericentromeric deletions, including those with
breakpoints in the q-arm close to the centromere (from 15 to 27.5
Mb from p-ter), were considered (Figure S1).
These results support the observations of our dataset and
confirm the prognostic impact of del(17p11.2). However, the
prognostic impact of del(22q) could not be confirmed (p..05) in
this new independent sCRC series of patients.
Discussion
sCRC patients who do not show or develop distant metastasis
are often cured by surgical resection of the primary tumor with
optional administration of adjuvant therapy. However, when
metastasis to the liver and other organs occur, the chances of cure
are dramatically reduced. Despite the fact that the understanding
of the genetic mechanisms underlying the early stages of both
familial [16] and sporadic CRC has significantly advanced in
recent years [17], the genetic mechanisms responsible for
progression of sCRC to a metastatic phenotype still remain poorly
understood. In this study, we investigated the pattern of numerical
chromosomal alterations of primary tumors from metastatic sCRC
that exhibited synchronous liver metastases versus non-metastatic
sCRC. In order to avoid false-negative non-metastatic cases, in
this later group only sCRC with a relative long follow up (median
follow-up of 99 months) were selected for the non-metastatic
tumor group. Similarly, only liver metastatic cases who had
undergone complete resection of both their primary and
metastatic tumor, were included in the metastatic patient group.
iFISH probes targeting those chromosomal regions more
frequently altered in sCRC [6] were specifically applied to the
cytogenetic characterization of both patient groups and a new
probe for the definition of del(17p) associated with breakpoints at
chromosome 17p11.2, was also systematically used. In line with
previous observations which show that liver metastatic and non-
metastatic sCRC share multiple chromosomal alterations (e.g.
Figure 2. Schematic representation of the network of interactions observed between genes encoded at the 17p11.2 (genes
highlighted in red), 17p13.1 (genes highlighted in green) and 22q11.2 (genes highlighted in blue) chromosomal regions, and
molecules downstream molecules regulated by these genes which have been associated with cancer or cancer related signalling
pathways. Genes highlighted in yellow are encoded at the three chromosomal regions referred above and they have been previously associated
with cancer; genes highlighted in grey are considered as biomarkers for sCRC.
doi:10.1371/journal.pone.0042683.g002
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gains of chromosomes 7, 8q, 13q and 20q and losses of the 1p, 8p,
14q, 17p, 18q and 22q chromosomes) [7,18–20], here we also
found a similar distribution between liver metastatic and non-
metastatic tumors for most chromosomal alterations identified. In
contrast, del(22q) and del(17p) (particularly when associated with
breakpoints at chromosome 17p11.2), were significantly more
prevalent or even restricted, to liver metastatic tumors. These later
findings support a potential role for both del(17p11.2) and del(22q)
in the metastatic process of sCRC to the liver.
Previous reports based on cytogenetic analyses of metastatic
disease from colorectal tumors indicated that chromosome 17p is
frequently lost in sCRC [21,22]. In line with other studies and
using similar methodological approaches, our results showed the
presence of del(17p13) in almost half of the sCRC cases studied
Table 3. List of genes encoded at chromosomal regions identified as being deleted by iFISH probes directed against the 17p11.2
(20156497 bp to 22975771 bp), 17p13.1 (7449445 bp to 7594642 bp) and 22q11.2 (21852397 bp to 21984023 bp) chromosomal
regions: gene name, cell localization and function.
Coded name Gene Cellular localization Function
17p11.2
C17orf103 Chromosome 17 open reading frame 103 Unknown Unknown
C17orf51 Chromosome 17 open reading frame 51 Unknown Unknown
CCDC144C Coiled-coil domain containing 144C Unknown Unknown
CCDC144NL Coiled-coil domain containing 144 family, N-terminal like Unknown Unknown
CDRT15L CMT1A duplicated region transcript 15-like 2 Unknown Unknown
DHRS7B Dehydrogenase/reductase (SDR family) member 7B Unknown Metabolism
FAM106B Family with sequence similarity 106, member B Unknown Unknown
FAM27L Family with sequence similarity 27-like Unknown Unknown
KCNJ12 Potassium inwardly-rectifying channel, subfamily J, member 12 Membrane Transport
LGALS9B Lectin, galactoside-binding, soluble, 9B Cytoplasm Cell-cell adhesion
MAP2K3 Mitogen-activated protein kinase kinase 3 Cytoplasm Cell death
MTRNR2L1 MT-RNR2-like 1 Unknown Unknown
SPECC1 Sperm antigen with calponin homology and coiled-coil domains 1 Nucleus Unknown
TMEM11 Transmembrane protein 11 Membrane Transport
USP22 Ubiquitin specific peptidase 22 Nucleus Cell cycle
17p13.1
ATP1B2 ATPase, Na+/K+ transporting, beta 2 polypeptide Membrane Metabolism
CD68 CD68 molecule Membrane Metabolism
EIF4A1 eukaryotic translation initiation factor 4A1 Cytoplasm Metabolism
FXR2 fragile X mental retardation, autosomal homolog 2 Cytoplasm Metabolism
MPDU1 mannose-P-dolichol utilization defect 1 Cytoplasm Metabolism
SAT2 spermidine/spermine N1-acetyltransferase family member 2 Membrane Metabolism
SENP3 SUMO1/sentrin/SMT3 specific peptidase 3 Nucleus Metabolism
SHBG sex hormone-binding globulin Extracellular Cell death
SNORA67 small nucleolar RNA, H/ACA box 67 Unknown Unknown
SNORD10 small nucleolar RNA, C/D box 10 Unknown Unknown
SOX15 SRY (sex determining region Y)-box 15 Nucleus Cell differentiation
TNFSF12 tumor necrosis factor (ligand) superfamily, member 12 Extracellular Cell death
TNFSF13 tumor necrosis factor (ligand) superfamily, member 13 Extracellular Cell death
TP53 tumor protein p53 Nucleus Apoptosis
WRAP53 WD repeat containing, antisense to TP53 Nucleus Telomerase activity
22q11.2
PI4KAP2 Phosphatidylinositol 4-kinase, catalytic, alpha pseudogene 2 Unknown Metabolism
RIMBP3 RIMS binding protein 3 Nucleus Unknown
SCARNA17 Small Cajal body-specific RNA 17 Unknown Unknown
SCARNA18 Small Cajal body-specific RNA 18 Unknown Unknown
UBE2L3 Ubiquitin-conjugating enzyme E2L 3 Cytoplasm Metabolism
YDJC YdjC homolog (bacterial) Unknown Metabolism
Genes which have been associated with cancer are shown in bold.
doi:10.1371/journal.pone.0042683.t003
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[23,24]; The frequency of del(17p13) was also significantly higher
in liver metastatic than non-metastatic cases, as has been suggested
by other groups [25–27]. It was noted that among cases with
del(17p13), occurrence of a breakpoint at chromosome 17p11.2
was mostly restricted to metastatic sCRC. Coinciding with these
observations, several authors have previously found that losses of
chromosome 17p in metastatic CRC samples cover larger regions
than in primary tumors, suggesting that unknown suppressor
genes, other than the TP53 gene, could be involved in the newly
deleted 17p sequences [28]. If this is confirmed, then these
differences could explain why cases with del(17p) in the absence of
TP53 mutations, also occur in advanced sCRC. Moreover, it
provides evidence for the potential existence of new additional
tumor suppressor genes (and potentially also oncogenes) coded in
the centromeric portion of chromosome 17p, proximal to TP53. In
this regard, it should be noted that several cancer associated genes
(e.g.: KCNJ12, MAP2K3, and USP22) are coded in this chromo-
somal region, the first gene systematically deleted at this break-
point region being a gene of unknown function (FAM27L).
Interestingly, genetic polymorphisms involving this chromosomal
region including the FAM27L gene, have been recently associated
with an increased risk for chronic myeloid leukemia [29]. Further
studies, in which mutations of this gene and deletions at
chromosome 17p11.2 are searched for, may indicate their
potential role in sCRC liver metastasis. Among other genes the
MAP2K3 gene is also coded in chromosome 17 region found to be
commonly deleted in metastatic sCRC. MAP2K3 is a strong
promoter of tumor invasion, progression and short survival in
several human cancers [30] and previous studies have shown that
decreased expression of MAP2K3 is associated with human breast
infiltrating ductal carcinomas [31]; similarly, non-synonymous
coding SNPs downregulating KCNJ12 expression have been
related with rhabdomyosarcomas [32], supporting a potential role
for both genes in liver metastatic sCRC. However, in this
chromosomal region, also some oncogenes are coded such as the
USP22 gene. Recent studies have shown that aberrant expression
of USP22 is associated with liver metastasis and poor prognosis
[33], due to the fact that this gene positively regulates cell cycle via
both the BMI-1-mediated INK4a/ARF pathway and the Atk
signaling pathway [34]. However, the activation and oncogenic
role of USP22 in the progression of sCRC is potentially linked to
genes encoded in other chromosomal regions such as the BMI-1
(10p13), CMYC (8q24) and CCND2 (12p13) genes [35].
In addition to del(17p11.2), in this study we also found an
association between losses of chromosome 22q and disease
outcome, in line with previous observations [26,36,37]. Previous
studies based on CGH analysis [38] have shown an association
between del(22q) and liver metastasis among sCRC patients;
similarly, Yana et al [39] showed that del(22q) correlates with the
Duke’s stage of the disease. Iino et al [26] have suggested that LOH
at chromosomes 17p, 18q, and 22q, is associated with an increased
metastatic potential of sCRC. In the latter study, LOH at
chromosome 17p was also significantly associated with vascular
invasion, whereas 18q and 22q LOH correlated more with
lymphatic dissemination of the disease; importantly, only LOH of
chromosome 22q showed a significant association with the
presence of lymph node metastasis. Thus, it could be hypothesized
that in sCRC, these three chromosomal losses may be specifically
associated with the metastatic process. If this holds true, screening
for genetic abnormalities of primary sCRC tumors could be useful
for predicting the metastatic potential which exists at the time of
diagnosis [40]. It should be emphasized that analysis of
del(17p11.2) in paired primary tumors and liver metastases from
sCRC patients showed either presence or absence of these
chromosomal changes in both (paired) tumor samples in all but
two cases; in these later two cases, del(17p11.2) was only detected
by SNP-arrays in the liver metastatic tumor.
Multivariate analysis of prognostic factors for OS, showed the
independent prognostic value of the two chromosomal abnormal-
ities, del(17p) with a breakpoint at 17p11.2 and del(22q);
Figure 3. Clinical, biological and genetic characteristics of sCRC patients which showed a significant impact on overall survival in
the univariate analysis: (A) carcinoembryonic antigen (CEA), (B) gender, (C) lymph node involvement, (D) occurrence of distant metastasis, (E)
chromosome 17 status, (F) del(17p11.2) (G) chromosome 22 status, and (H) prognostic score established on the basis of the two most informative
independent prognostic factors -del(17p11.2) and chromosome 22 status; p,.0001-.
doi:10.1371/journal.pone.0042683.g003
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consequently, coexistence of both chromosomal alterations was
associated with a significantly reduced OS vs. cases which showed
neither of these alterations (OS at 5 years of 0% versus 93%,
respectively). Despite the fact that an association has been reported
between different chromosomal abnormalities and the prognosis of
sCRC [18], to the best of our knowledge this is the first report in
which the independent prognostic value of del(17p) with a
breakpoint at 17p11.2 and of del(22q) is described. Preliminary
results using genome-wide array analyses have shown an
association between specific genetic alterations present in primary
sCRC tumors and patient survival [10,18,22]. Poulogiannis et al
(using a DNA microarray platform covering the entire genome at
an average of 1 Mb of resolution) identified DNA copy number
losses at 18q12.2 to be an independent prognostic marker [10]. In
the current study, we have re-analyzed this dataset and confirmed
the prognostic value of del(17p) including that of del(17p) with a
breakpoint at 17p11.2; in contrast, the clinical impact of del(22q)
could not be validated in this series. Although the precise clinical
value of del(22q) should be investigated further, validation of our
data concerning the prognostic impact of the 17p11.2 breakpoint
in an independent dataset (in spite of the substantial differences in
the technologies applied in both studies) strengthens the evidence
for the clinical relevance of chromosome 17p deletions encom-
passing genomic regions beyond the TP53 locus, and points to the
potential role of other candidate genes coded at chromosome 17p
centromericly to TP53. As discussed above, such genes include the
MAP2K3, KCNJ12 and USP22 genes [30–35]. Interestingly, when
we searched for direct interactions among the deleted genes and
other cancer-associated genes, 30 genes deleted in cases with
del(17p), and another 6 genes deleted in cases with del(22q),
emerged as directly related to signaling pathways involved in cell
growth and proliferation (e.g., EGFR and CDK1A) as well as in cell
death (e.g., BAX and BCL2). These findings suggest a potential role
for the combined deletion of these genes in conferring poor-
prognosis to sCRC with coexisting del(17p) and del(22q), possibly
due to increased cell proliferation and survival and diminished
DNA repair.
In summary, in the present study we show that the presence of
del(17p) with a breakpoint at 17p11.2 is an independent adverse
prognostic factor for OS of sCRC. When combined with
del(22q11.2) it allowed the identification of three groups of sCRC
patients with significantly different outcome, which could be
predicted at diagnosis. Further prospective studies are required in
larger series of sCRC patients to confirm the prognostic value of
the combined assessment of del(17p) and del(22q) in primary
tumor samples at diagnosis and the precise role of the deleted
genes.
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